Pharmaceutical company Sandoz reported on Monday the commercial launch of Treprostinil Injection in the US PAH market, with 180 days of marketing exclusivity.
According to the company, Treprostinil is indicated for Pulmonary Arterial Hypertension (PAH), a progressive disease resulting in heart failure and shortened life expectancy. About 52,000 patients have been diagnosed with PAH in the US, with rates expected to rise due to increased survival and diagnosis rates.
Treprostinil Injection is the first fully substitutable AB rated generic version of Remodulin (treprostinil) Injection sold by United Therapeutics Corporation.
Under the terms of an agreement, Sandoz will collaborate with RareGen LLC to commercialise Treprostinil Injection, which is supplied in 20 ml multi-dose vials in four strengths:20 mg, 50 mg, 100 mg, or 200 mg (1 mg/ml, 2.5 mg/ml, 5 mg/ml or 10 mg/ml). RareGen LLC is backed by PBM Capital Group, a healthcare investor.
In FY 2018, the global sales for Treprostinil were approximately USD599m, according to United Therapeutics Corporation.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling